Large pharma companies at Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

11 large pharma companies are at Antibody Engineering 2026 — 24 presentations on the program. Most represented: AstraZeneca (3 on the program), Genentech (3 on the program), Regeneron (3 on the program). 6 of them have their own page in this guide. As of Sep 26, 2026.

All 153 organizations at Antibody Engineering 2026 →

Showing 1–11 of 11 organizations

Organization	Antibody Engineering 2026 Attendance
AstraZeneca Cambridge, United Kingdom
astrazeneca.com Large pharma Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases.	Talk Sun Dec 13 11:00am–11:45am Career Path/Experiences Panel Discussion Early Career Scientist Session · with Macaw Therapeutics, Genentech Keynote Mon Dec 14 10:20am–10:55am From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients. ADCs & conjugates Talk Wed Dec 16 10:30am–11:00am CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions. Talk Wed Dec 16 2:10pm–2:15pm Co-Chairs' Remarks Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms · with Washington University School of Medicine Talk Wed Dec 16 2:15pm–2:45pm Expanding the Toolbox: Non-natural Amino Acids Enable Development of a CD30 Dual-payload ADC Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Genentech South San Francisco, CA
gene.com Large pharma Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines.	Talk Sun Dec 13 11:00am–11:45am Career Path/Experiences Panel Discussion Early Career Scientist Session · with Macaw Therapeutics, AstraZeneca Talk Mon Dec 14 2:30pm–3:00pm Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed. Bispecifics & multispecifics Talk Tue Dec 15 8:10am–8:15am Co-Chairs’ Remarks Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Johnson & Johnson Talk Tue Dec 15 8:15am–8:45am From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes. Protein engineering
Regeneron Tarrytown, NY
regeneron.com Large pharma Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.	Talk Sun Dec 13 3:45pm–4:15pm From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule. Talk Mon Dec 14 5:15pm–5:45pm Targeting IgE Responses Track 2: Engineering Solutions for Accessing Difficult Targets Beyond oncology Talk Wed Dec 16 8:10am–8:15am Co-Chairs’ Remarks Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
Amgen Thousand Oaks, CA
amgen.com Large pharma Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.	Talk Sun Dec 13 1:00pm–1:15pm Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor Talk Sun Dec 13 1:15pm–1:45pm Developability-Guided Generative Biology for Therapeutic Protein Engineering Designing new therapeutic proteins by computer while checking from the start that they can be made and purified. AI & computational design Talk Sun Dec 13 4:15pm–5:00pm Moderated Panel Discussion with Session Speakers Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Chugai Pharmaceutical Tokyo, Japan
chugai-pharm.co.jp Large pharma Japanese pharmaceutical company and Roche Group member known for antibody engineering technologies such as recycling and bispecific antibodies.	Talk Mon Dec 14 3:30pm–4:00pm Protease-Activated IL-12 Masking via Engineered VH Dissociation and IL-12 Intrinsic activity Enables Tunable Cytokine Activation Caging a powerful immune-signaling protein so it only switches on where tumor enzymes cut the cage open. Talk Tue Dec 15 4:45pm–5:15pm Long Acting Anti-latent TGF-β1 Recycling Antibody for Fibrotic Diseases An antibody that is recycled back out of cells, letting it block a scarring-driving growth factor for far longer. Protein engineering
Johnson & Johnson New Brunswick, NJ
jnj.com Large pharma Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines.	Talk Sun Dec 13 2:15pm–2:45pm Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats. Talk Tue Dec 15 8:10am–8:15am Co-Chairs’ Remarks Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Genentech
EMD Serono Rockland, MA
emdserono.com Large pharma US and Canadian healthcare business of Merck KGaA, Darmstadt, developing medicines in oncology, neurology and fertility.	Talk Sun Dec 13 1:45pm–2:15pm A Combined Computational and Experimental Cascade for Variable Domain Assessment and Optimization Towards Developable Multispecific Antibodies Splitting a multi-target antibody into its binding pieces and improving each one without losing target binding. AI & computational design
Gilead Sciences Foster City, CA
gilead.com Large pharma Biopharmaceutical company with marketed medicines in virology, oncology and inflammation, including an antibody-drug conjugate.	Talk Tue Dec 15 3:00pm–3:30pm Development of a PRAME pMHC Targeted T Cell Engager for Solid Tumor Therapy Finding antibodies that recognize a cancer protein fragment displayed on tumor cells, then using them to steer T cells to kill.
Incyte Wilmington, DE
incyte.com Large pharma Biopharmaceutical company discovering, developing and selling medicines in oncology and inflammation and autoimmunity.	Talk Tue Dec 15 5:45pm–6:15pm An Integrated Structure Biology Strategy for TCR Antibody Discovery Why the T-cell receptor is hard to target, and how high-resolution imaging of antibody binding sites guides better antibody choices. Protein engineering
Merck Rahway, NJ
merck.com Large pharma Global pharmaceutical company, known as MSD outside the US and Canada, developing medicines, vaccines and biologics.	Talk Wed Dec 16 4:45pm–5:15pm uPAR Targeting Cytotoxic Antibody Drug Conjugates Selectively Deplete Proinflammatory Myeloid Cells for Autoimmune Indications Using single-cell data to pick a marker on inflammatory immune cells in rheumatoid arthritis, then killing those cells with a drug-carrying antibody. Beyond oncology
Sanofi Paris, France
sanofi.com Large pharma Global pharmaceutical company developing medicines and vaccines, including antibodies for immunology and inflammatory diseases.	Talk Wed Dec 16 2:15pm–2:45pm The Bispecific and Multispecific Revolution in Antibody Therapeutics for Autoimmune and Inflammatory Diseases Why antibodies that hit two or more targets, so far mostly cancer drugs, are now being tried in autoimmune and inflammatory disease. Bispecifics & multispecificsBeyond oncology